Nevirapine resistance and breast-milk HIV transmission

Effects of single and extended-dose nevirapine prophylaxis in subtype C HIV-infected infants

Anitha Moorthy, Amita Gupta, Ramesh Bhosale, Srikanth Tripathy, Jayagowri Sastry, Smita Kulkarni, Madhuri Thakar, Renu Bharadwaj, Anju Kagal, Arvind V. Bhore, Sandesh Patil, Vandana Kulkarni, Varadharajan Venkataramani, Usha Balasubramaniam, Nishi Suryavanshi, Carrie Ziemniak, Nikhil Gupte, Robert C Bollinger, Deborah Persaud

Research output: Contribution to journalArticle

Abstract

Background: Daily nevirapine (NVP) prophylaxis to HIV-exposed infants significantly reduces breast-milk HIV transmission. We assessed NVP-resistance in Indian infants enrolled in the "six-week extended-dose nevirapine" (SWEN) trial who received single-dose NVP (SD-NVP) or SWEN for prevention of breast-milk HIV transmission but who also acquired subtype C HIV infection during the first year of life. Methods/Findings: Standard population sequencing and cloning for viral subpopulations present at ≥5% frequency were used to determine HIV genotypes from 94% of the 79 infected Indian infants studied. Timing of infection was defined based on when an infant's blood sample first tested positive for HIV DNA. SWEN-exposed infants diagnosed with HIV by six weeks of age had a significantly higher prevalence of NVP-resistance than those who received SD-NVP, by both standard population sequencing (92% of 12 vs. 38% of 29; p = 0.002) and low frequency clonal analysis (92% of 12 vs. 59% of 29; p = 0.06). Likelihood of infection with NVP-resistant HIV through breast-milk among infants infected after age six weeks was substantial, but prevalence of NVP-resistance did not differ among SWEN or SD-NVP exposed infants by standard population sequencing (15% of 13 vs. 15% of 20; p = 1.00) and clonal analysis (31% of 13 vs. 40% of 20; p = 0.72). Types of NVP-resistance mutations and patterns of persistence at one year of age were similar between the two groups. NVP-resistance mutations did differ by timing of HIV infection; the Y181C variant was predominant among infants diagnosed in the first six weeks of life, compared to Y188C/H during late breast-milk transmission. Conclusions/Significance: Use of SWEN to prevent breast-milk HIV transmission carries a high likelihood of resistance if infection occurs in the first six weeks of life. Moreover, there was a continued risk of transmission of NVP-resistant HIV through breastfeeding during the first year of life, but did not differ between SD-NVP and SWEN groups. As with SD-NVP, the value of preventing HIV infection in a large number of infants should be considered alongside the high risk of resistance associated with extended NVP prophylaxis.

Original languageEnglish (US)
Article numbere4096
JournalPLoS One
Volume4
Issue number1
DOIs
StatePublished - Jan 1 2009

Fingerprint

Nevirapine
Human Milk
breast milk
disease control
HIV
dosage
HIV infections
HIV Infections
infection
mutation
breast feeding
Infection
Population
molecular cloning
Mutation
Cloning

ASJC Scopus subject areas

  • Agricultural and Biological Sciences(all)
  • Biochemistry, Genetics and Molecular Biology(all)
  • Medicine(all)

Cite this

Nevirapine resistance and breast-milk HIV transmission : Effects of single and extended-dose nevirapine prophylaxis in subtype C HIV-infected infants. / Moorthy, Anitha; Gupta, Amita; Bhosale, Ramesh; Tripathy, Srikanth; Sastry, Jayagowri; Kulkarni, Smita; Thakar, Madhuri; Bharadwaj, Renu; Kagal, Anju; Bhore, Arvind V.; Patil, Sandesh; Kulkarni, Vandana; Venkataramani, Varadharajan; Balasubramaniam, Usha; Suryavanshi, Nishi; Ziemniak, Carrie; Gupte, Nikhil; Bollinger, Robert C; Persaud, Deborah.

In: PLoS One, Vol. 4, No. 1, e4096, 01.01.2009.

Research output: Contribution to journalArticle

Moorthy, A, Gupta, A, Bhosale, R, Tripathy, S, Sastry, J, Kulkarni, S, Thakar, M, Bharadwaj, R, Kagal, A, Bhore, AV, Patil, S, Kulkarni, V, Venkataramani, V, Balasubramaniam, U, Suryavanshi, N, Ziemniak, C, Gupte, N, Bollinger, RC & Persaud, D 2009, 'Nevirapine resistance and breast-milk HIV transmission: Effects of single and extended-dose nevirapine prophylaxis in subtype C HIV-infected infants', PLoS One, vol. 4, no. 1, e4096. https://doi.org/10.1371/journal.pone.0004096
Moorthy, Anitha ; Gupta, Amita ; Bhosale, Ramesh ; Tripathy, Srikanth ; Sastry, Jayagowri ; Kulkarni, Smita ; Thakar, Madhuri ; Bharadwaj, Renu ; Kagal, Anju ; Bhore, Arvind V. ; Patil, Sandesh ; Kulkarni, Vandana ; Venkataramani, Varadharajan ; Balasubramaniam, Usha ; Suryavanshi, Nishi ; Ziemniak, Carrie ; Gupte, Nikhil ; Bollinger, Robert C ; Persaud, Deborah. / Nevirapine resistance and breast-milk HIV transmission : Effects of single and extended-dose nevirapine prophylaxis in subtype C HIV-infected infants. In: PLoS One. 2009 ; Vol. 4, No. 1.
@article{c8e578de46154de2ab2bf8518196f9d5,
title = "Nevirapine resistance and breast-milk HIV transmission: Effects of single and extended-dose nevirapine prophylaxis in subtype C HIV-infected infants",
abstract = "Background: Daily nevirapine (NVP) prophylaxis to HIV-exposed infants significantly reduces breast-milk HIV transmission. We assessed NVP-resistance in Indian infants enrolled in the {"}six-week extended-dose nevirapine{"} (SWEN) trial who received single-dose NVP (SD-NVP) or SWEN for prevention of breast-milk HIV transmission but who also acquired subtype C HIV infection during the first year of life. Methods/Findings: Standard population sequencing and cloning for viral subpopulations present at ≥5{\%} frequency were used to determine HIV genotypes from 94{\%} of the 79 infected Indian infants studied. Timing of infection was defined based on when an infant's blood sample first tested positive for HIV DNA. SWEN-exposed infants diagnosed with HIV by six weeks of age had a significantly higher prevalence of NVP-resistance than those who received SD-NVP, by both standard population sequencing (92{\%} of 12 vs. 38{\%} of 29; p = 0.002) and low frequency clonal analysis (92{\%} of 12 vs. 59{\%} of 29; p = 0.06). Likelihood of infection with NVP-resistant HIV through breast-milk among infants infected after age six weeks was substantial, but prevalence of NVP-resistance did not differ among SWEN or SD-NVP exposed infants by standard population sequencing (15{\%} of 13 vs. 15{\%} of 20; p = 1.00) and clonal analysis (31{\%} of 13 vs. 40{\%} of 20; p = 0.72). Types of NVP-resistance mutations and patterns of persistence at one year of age were similar between the two groups. NVP-resistance mutations did differ by timing of HIV infection; the Y181C variant was predominant among infants diagnosed in the first six weeks of life, compared to Y188C/H during late breast-milk transmission. Conclusions/Significance: Use of SWEN to prevent breast-milk HIV transmission carries a high likelihood of resistance if infection occurs in the first six weeks of life. Moreover, there was a continued risk of transmission of NVP-resistant HIV through breastfeeding during the first year of life, but did not differ between SD-NVP and SWEN groups. As with SD-NVP, the value of preventing HIV infection in a large number of infants should be considered alongside the high risk of resistance associated with extended NVP prophylaxis.",
author = "Anitha Moorthy and Amita Gupta and Ramesh Bhosale and Srikanth Tripathy and Jayagowri Sastry and Smita Kulkarni and Madhuri Thakar and Renu Bharadwaj and Anju Kagal and Bhore, {Arvind V.} and Sandesh Patil and Vandana Kulkarni and Varadharajan Venkataramani and Usha Balasubramaniam and Nishi Suryavanshi and Carrie Ziemniak and Nikhil Gupte and Bollinger, {Robert C} and Deborah Persaud",
year = "2009",
month = "1",
day = "1",
doi = "10.1371/journal.pone.0004096",
language = "English (US)",
volume = "4",
journal = "PLoS One",
issn = "1932-6203",
publisher = "Public Library of Science",
number = "1",

}

TY - JOUR

T1 - Nevirapine resistance and breast-milk HIV transmission

T2 - Effects of single and extended-dose nevirapine prophylaxis in subtype C HIV-infected infants

AU - Moorthy, Anitha

AU - Gupta, Amita

AU - Bhosale, Ramesh

AU - Tripathy, Srikanth

AU - Sastry, Jayagowri

AU - Kulkarni, Smita

AU - Thakar, Madhuri

AU - Bharadwaj, Renu

AU - Kagal, Anju

AU - Bhore, Arvind V.

AU - Patil, Sandesh

AU - Kulkarni, Vandana

AU - Venkataramani, Varadharajan

AU - Balasubramaniam, Usha

AU - Suryavanshi, Nishi

AU - Ziemniak, Carrie

AU - Gupte, Nikhil

AU - Bollinger, Robert C

AU - Persaud, Deborah

PY - 2009/1/1

Y1 - 2009/1/1

N2 - Background: Daily nevirapine (NVP) prophylaxis to HIV-exposed infants significantly reduces breast-milk HIV transmission. We assessed NVP-resistance in Indian infants enrolled in the "six-week extended-dose nevirapine" (SWEN) trial who received single-dose NVP (SD-NVP) or SWEN for prevention of breast-milk HIV transmission but who also acquired subtype C HIV infection during the first year of life. Methods/Findings: Standard population sequencing and cloning for viral subpopulations present at ≥5% frequency were used to determine HIV genotypes from 94% of the 79 infected Indian infants studied. Timing of infection was defined based on when an infant's blood sample first tested positive for HIV DNA. SWEN-exposed infants diagnosed with HIV by six weeks of age had a significantly higher prevalence of NVP-resistance than those who received SD-NVP, by both standard population sequencing (92% of 12 vs. 38% of 29; p = 0.002) and low frequency clonal analysis (92% of 12 vs. 59% of 29; p = 0.06). Likelihood of infection with NVP-resistant HIV through breast-milk among infants infected after age six weeks was substantial, but prevalence of NVP-resistance did not differ among SWEN or SD-NVP exposed infants by standard population sequencing (15% of 13 vs. 15% of 20; p = 1.00) and clonal analysis (31% of 13 vs. 40% of 20; p = 0.72). Types of NVP-resistance mutations and patterns of persistence at one year of age were similar between the two groups. NVP-resistance mutations did differ by timing of HIV infection; the Y181C variant was predominant among infants diagnosed in the first six weeks of life, compared to Y188C/H during late breast-milk transmission. Conclusions/Significance: Use of SWEN to prevent breast-milk HIV transmission carries a high likelihood of resistance if infection occurs in the first six weeks of life. Moreover, there was a continued risk of transmission of NVP-resistant HIV through breastfeeding during the first year of life, but did not differ between SD-NVP and SWEN groups. As with SD-NVP, the value of preventing HIV infection in a large number of infants should be considered alongside the high risk of resistance associated with extended NVP prophylaxis.

AB - Background: Daily nevirapine (NVP) prophylaxis to HIV-exposed infants significantly reduces breast-milk HIV transmission. We assessed NVP-resistance in Indian infants enrolled in the "six-week extended-dose nevirapine" (SWEN) trial who received single-dose NVP (SD-NVP) or SWEN for prevention of breast-milk HIV transmission but who also acquired subtype C HIV infection during the first year of life. Methods/Findings: Standard population sequencing and cloning for viral subpopulations present at ≥5% frequency were used to determine HIV genotypes from 94% of the 79 infected Indian infants studied. Timing of infection was defined based on when an infant's blood sample first tested positive for HIV DNA. SWEN-exposed infants diagnosed with HIV by six weeks of age had a significantly higher prevalence of NVP-resistance than those who received SD-NVP, by both standard population sequencing (92% of 12 vs. 38% of 29; p = 0.002) and low frequency clonal analysis (92% of 12 vs. 59% of 29; p = 0.06). Likelihood of infection with NVP-resistant HIV through breast-milk among infants infected after age six weeks was substantial, but prevalence of NVP-resistance did not differ among SWEN or SD-NVP exposed infants by standard population sequencing (15% of 13 vs. 15% of 20; p = 1.00) and clonal analysis (31% of 13 vs. 40% of 20; p = 0.72). Types of NVP-resistance mutations and patterns of persistence at one year of age were similar between the two groups. NVP-resistance mutations did differ by timing of HIV infection; the Y181C variant was predominant among infants diagnosed in the first six weeks of life, compared to Y188C/H during late breast-milk transmission. Conclusions/Significance: Use of SWEN to prevent breast-milk HIV transmission carries a high likelihood of resistance if infection occurs in the first six weeks of life. Moreover, there was a continued risk of transmission of NVP-resistant HIV through breastfeeding during the first year of life, but did not differ between SD-NVP and SWEN groups. As with SD-NVP, the value of preventing HIV infection in a large number of infants should be considered alongside the high risk of resistance associated with extended NVP prophylaxis.

UR - http://www.scopus.com/inward/record.url?scp=58149464331&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=58149464331&partnerID=8YFLogxK

U2 - 10.1371/journal.pone.0004096

DO - 10.1371/journal.pone.0004096

M3 - Article

VL - 4

JO - PLoS One

JF - PLoS One

SN - 1932-6203

IS - 1

M1 - e4096

ER -